12.06.21
Private equity firm GTCR’s portfolio company Resonetics has sold a minority equity stake to funds affiliated with global investment firm Carlyle, valuing the company at approximately $2.25 billion. Carlyle will join GTCR as a meaningful shareholder in Resonetics as a result of the transaction.
Founded in 1987 and headquartered in Nashua, N.H., Resonetics specializes in micro-manufacturing for medical devices, targeting fast-growing interventional and minimally-invasive applications across the MedTech industry. The Company is focused on fabricating highly technical componentry for complex medical device applications, serving end-markets that are experiencing robust growth as clinicians shift away from higher-risk, invasive procedures, towards more interventional approaches. Resonetics has established itself as a mission-critical supplier enabling innovations in several high growth MedTech end-markets including diabetes, neurovascular, ophthalmology, interventional cardiology, and structural heart, among others.
GTCR made its initial investment in Resonetics in partnership with MedTech industry executive Robert "Chip" Hance. Consistent with its Leaders Strategy approach, GTCR initially partnered with Hance to form Regatta Medical in April 2017 to pursue opportunities in the medical device sector. Since GTCR's investment, GTCR and Hance have partnered with the Resonetics management team, led by CEO Tom Burns, to significantly grow the company's revenue and EBITDA through investments in strong organic growth and strategic add-on acquisitions.
"We've appreciated the opportunity to invest in Resonetics, supporting its organic growth initiatives and its eight add-on acquisitions, including the recent acquisitions of FISO Technologies and Hudson Medical Innovations, during our ownership," said Sean Cunningham, Managing Director at GTCR. "We are thrilled to continue our partnership with Chip Hance, Tom Burns, and the entire Resonetics management team as they look to build on their success in the coming years," he added.
"Our business has advanced significantly over the past four years, as we've expanded our production capacity, grown our facility footprint and built greater scale," said Tom Burns, CEO, Resonetics. "We have enjoyed the outstanding partnership with GTCR as we've built Resonetics and are excited to be partnering with GTCR and Carlyle in this next chapter as we continue to grow our business and enhance our product capabilities to better serve our customers."
"We have been extraordinarily impressed with the growth and development of Resonetics over the last several years and are looking forward to our ongoing partnership with the Company," added GTCR Co-CEO and Managing Director Dean Mihas. "I want to thank Chip Hance and Tom Burns for their outstanding leadership and look forward to our next chapter with the entire Resonetics team and our partners at Carlyle."
Kirkland & Ellis acted as legal advisor and Piper Sandler acted as financial advisor to Resonetics and GTCR. Debevoise & Plimpton acted as legal advisor and Barclays acted as financial advisor to Carlyle.
Founded in 1987 and headquartered in Nashua, N.H., Resonetics specializes in micro-manufacturing for medical devices, targeting fast-growing interventional and minimally-invasive applications across the MedTech industry. The Company is focused on fabricating highly technical componentry for complex medical device applications, serving end-markets that are experiencing robust growth as clinicians shift away from higher-risk, invasive procedures, towards more interventional approaches. Resonetics has established itself as a mission-critical supplier enabling innovations in several high growth MedTech end-markets including diabetes, neurovascular, ophthalmology, interventional cardiology, and structural heart, among others.
GTCR made its initial investment in Resonetics in partnership with MedTech industry executive Robert "Chip" Hance. Consistent with its Leaders Strategy approach, GTCR initially partnered with Hance to form Regatta Medical in April 2017 to pursue opportunities in the medical device sector. Since GTCR's investment, GTCR and Hance have partnered with the Resonetics management team, led by CEO Tom Burns, to significantly grow the company's revenue and EBITDA through investments in strong organic growth and strategic add-on acquisitions.
"We've appreciated the opportunity to invest in Resonetics, supporting its organic growth initiatives and its eight add-on acquisitions, including the recent acquisitions of FISO Technologies and Hudson Medical Innovations, during our ownership," said Sean Cunningham, Managing Director at GTCR. "We are thrilled to continue our partnership with Chip Hance, Tom Burns, and the entire Resonetics management team as they look to build on their success in the coming years," he added.
"Our business has advanced significantly over the past four years, as we've expanded our production capacity, grown our facility footprint and built greater scale," said Tom Burns, CEO, Resonetics. "We have enjoyed the outstanding partnership with GTCR as we've built Resonetics and are excited to be partnering with GTCR and Carlyle in this next chapter as we continue to grow our business and enhance our product capabilities to better serve our customers."
"We have been extraordinarily impressed with the growth and development of Resonetics over the last several years and are looking forward to our ongoing partnership with the Company," added GTCR Co-CEO and Managing Director Dean Mihas. "I want to thank Chip Hance and Tom Burns for their outstanding leadership and look forward to our next chapter with the entire Resonetics team and our partners at Carlyle."
Kirkland & Ellis acted as legal advisor and Piper Sandler acted as financial advisor to Resonetics and GTCR. Debevoise & Plimpton acted as legal advisor and Barclays acted as financial advisor to Carlyle.